Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have been assigned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $37.67.

Several research analysts have recently commented on DAWN shares. Piper Sandler reiterated an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Friday, July 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday. Wedbush reiterated an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Finally, JPMorgan Chase & Co. upped their target price on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Monday, April 22nd.

Day One Biopharmaceuticals Trading Down 1.1 %

Day One Biopharmaceuticals stock opened at $15.19 on Friday. Day One Biopharmaceuticals has a 52 week low of $9.67 and a 52 week high of $18.07. The stock has a market cap of $1.33 billion, a P/E ratio of -6.05 and a beta of -1.51. The stock has a 50 day moving average of $14.01 and a 200-day moving average of $14.84.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Monday, May 6th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.05). As a group, equities analysts predict that Day One Biopharmaceuticals will post -2.69 earnings per share for the current fiscal year.

Insider Transactions at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 20,000 shares of the company’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $16.01, for a total value of $320,200.00. Following the completion of the sale, the insider now owns 1,121,081 shares of the company’s stock, valued at $17,948,506.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, General Counsel Adam Dubow sold 3,253 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $16.08, for a total value of $52,308.24. Following the sale, the general counsel now owns 21,731 shares of the company’s stock, valued at approximately $349,434.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Samuel C. Blackman sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $16.01, for a total value of $320,200.00. Following the completion of the sale, the insider now owns 1,121,081 shares of the company’s stock, valued at approximately $17,948,506.81. The disclosure for this sale can be found here. Over the last quarter, insiders sold 73,300 shares of company stock valued at $1,181,765. 8.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Day One Biopharmaceuticals by 8.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock valued at $56,807,000 after purchasing an additional 346,090 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Day One Biopharmaceuticals by 28.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock worth $30,935,000 after buying an additional 472,654 shares during the last quarter. Parkman Healthcare Partners LLC increased its holdings in shares of Day One Biopharmaceuticals by 34.2% in the fourth quarter. Parkman Healthcare Partners LLC now owns 625,749 shares of the company’s stock valued at $9,136,000 after buying an additional 159,341 shares in the last quarter. Braidwell LP lifted its position in shares of Day One Biopharmaceuticals by 13.5% during the 4th quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock valued at $61,547,000 after acquiring an additional 500,000 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its position in shares of Day One Biopharmaceuticals by 20.5% during the 4th quarter. New York State Common Retirement Fund now owns 78,299 shares of the company’s stock valued at $1,143,000 after acquiring an additional 13,294 shares during the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.